ORGS.OTC.PinkOrgenesis INC

Form 4: Orgenesis Inc. Director Ashish Nanda Acquires Stock Options

Sentiment:

SEC Form 4


Director Ashish Nanda reports acquisition of stock options in Orgenesis Inc.

Summary

  • On July 23, 2024, Ashish Nanda, a director of Orgenesis Inc., acquired stock options.
  • Nanda acquired 189,320 stock options with an exercise price of $0.64 and another 189,320 stock options with an exercise price of $1.03.
  • These options are exercisable starting July 23, 2024, and expire on July 22, 2034.
  • Following the transaction, Nanda directly owns 189,320 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock option acquisitions by a company director. It doesn't inherently indicate positive or negative performance.

Positives

  • The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions and doesn't necessarily reflect broader industry trends.

Stakeholder Impact

  • The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

DateDescription
07/23/2024Date of earliest transaction: Acquisition of stock options.
07/23/2024Date exercisable for both sets of stock options.
07/22/2034Expiration date for both sets of stock options.
07/25/2024Date of signature for the Form 4 filing.

Keywords

stock options, Form 4, director, ORGS, Orgenesis Inc., acquisition, Nanda, Ashish Nanda

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.